|
"pao w"的相關文件
顯示項目 36-39 / 39 (共4頁)
<< < 1 2 3 4
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2012 |
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
|
Girard, N.; Sima, C. S.; Jackman, D. M.; Sequist, L. V.; Chen, H.; Yang, J. C-H.; Ji, H.; Waltman, B.; Rosell, R.; Taron, M.; Zakowski, M. F.; Ladanyi, M.; Riely, G.; Pao, W.; 楊志新 |
| 國立臺灣大學 |
2008-06 |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
|
Yang, CH; Yu, CJ; Shih, JY; Chang, YC; Hu, FC; Tsai, MC; Chen, KY; Lin, ZZ; Huang, CJ; Shun, CT; Huang, CL; Bean, J; Cheng, AL; Pao, W; Yang, PC. |
| 國家衛生研究院 |
2007-12-26 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean, J; Brennan, C; Shih, JY; Riely, G; Viale, A; Wang, L; Chitale, D; Motoi, N; Szoke, J; Broderick, S; Balak, M; Chang, WC; Yu, CJ; Gazdar, A; Pass, H; Rusch, V; Gerald, W; Huang, SF; Yang, PC; Miller, V; Ladany, M; Yang, CH; Pao, W |
| 國家衛生研究院 |
2007-12 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean, J;Brennan, C;Shih, JY;Riely, G;Viale, A;Wang, L;Chitale, D;Motoi, N;Szoke, J;Broderick, S;Balak, M;Chang, WC;Yu, CJ;Gazdar, A;Pass, H;Rusch, V;Gerald, W;Huang, SF;Yang, PC;Miller, V;Ladanyi, M;Yang, CH;Pao, W |
顯示項目 36-39 / 39 (共4頁)
<< < 1 2 3 4
每頁顯示[10|25|50]項目
|
